Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Prostatic Neoplasms × Atrasentan × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Oligodendroglioma 1 Gliosarcoma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 26 Prednisone 15 Specimen Handling 14 Magnetic Resonance Spectroscopy 14 PROSTVAC 11 Biopsy 11 Goserelin 9 bicalutamide 8 Leuprolide 8 Estramustine 8 Radiotherapy 7 Bevacizumab 7 enzalutamide 6 Mitoxantrone 6 Lycopene 6 Flutamide 6 sargramostim 5 ixabepilone 5 Thalidomide 5 High-Intensity Focused Ultrasound Ablation 5 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 5 olaparib 4 cediranib 4 Radiation 4 Androgen Antagonists 4 luprolide acetate gel depot 3 cabozantinib 3 Watchful Waiting 3 Vorinostat 3 Tomography, X-Ray Computed 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00046943 2011-02-21

Atrasentan in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡